Heterotopic ossification or heterotopic ossificans (HO) is the abnormal formation of mature lamellar bone in the soft tissues, which was first described in 1692 by Patin, who termed it as myositis ossificans progressiva. HO can broadly be classified into genetic or non-genetic types (neurogenic and traumatic). The exact pathophysiology of HO is still unclear. When symptomatic, it presents as decreased range of motion associated with localized signs of inflammation. Radiographs, along with CT scans, are usually the most common modality for diagnosis of HO. Prompt and accurate diagnosis and timely preventive and treatment measures are key management strategies. Management can be divided into prophylaxis (anti-inflammatory drugs, bisphosphonates, and radiotherapy) and treatment (physical therapy and surgery) depending on the stage of presentation. Since most of the patients of HO are young adults of the productive age group, it is important to consider treatment-related adverse effects. In future, the incidence of HO can be reduced by research focusing on better understanding of pathophysiology, prevention, and treatment of HO.